D. Boral Capital Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price target decreased by analysts at D. Boral Capital from $3.00 to $2.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. D. Boral Capital’s price objective would suggest a potential upside of 212.01% from the stock’s previous close.

A number of other analysts have also issued reports on the stock. Maxim Group dropped their price objective on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Friday, January 31st.

Lineage Cell Therapeutics Trading Down 2.0 %

NYSEAMERICAN LCTX opened at $0.64 on Tuesday. The stock has a market capitalization of $141.29 million, a PE ratio of -5.34 and a beta of 1.21. Lineage Cell Therapeutics has a 1-year low of $0.48 and a 1-year high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LCTX. Defender Capital LLC. lifted its holdings in Lineage Cell Therapeutics by 19.2% in the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company’s stock worth $2,997,000 after purchasing an additional 961,150 shares during the period. Geode Capital Management LLC lifted its holdings in Lineage Cell Therapeutics by 2.3% in the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company’s stock worth $3,331,000 after purchasing an additional 83,274 shares during the period. Barclays PLC lifted its holdings in Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after purchasing an additional 159,924 shares during the period. State Street Corp lifted its holdings in Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company’s stock worth $2,361,000 after purchasing an additional 45,483 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Lineage Cell Therapeutics by 13.9% in the third quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company’s stock worth $613,000 after purchasing an additional 82,864 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.